FDA's Expedited Approval Mechanisms for New Drug Products

被引：53

作者：

Kepplinger, Erin E. ^{[1
]}

机构：

[1] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA

来源：

关键词：

INNOVATION; SAFETY;

D O I：

10.1089/blr.2015.9999

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

[No abstract available]

引用

页码：15 / 37

页数：23

共 85 条

[1] A survey of breakthrough therapy designations [J].

Aggarwal, Saurabh .

[2]

Aldes Jamie L, 2008, Health Matrix Clevel, V18, P463

[3]

American Cancer Society, MEL SKIN CANC WHAT A

[4]

[Anonymous], ZYDELIG

[5]

[Anonymous], 2014, ZYKADIA

[6]

[Anonymous], 2014, Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics

[7]

[Anonymous], 2014, ARZERRA

[8]

[Anonymous], PAV WAY PERS MED FDA

[9]

[Anonymous], 2014, IMBRUVICA

[10]

[Anonymous], 2014, HARVONI